Faron Pharmaceuticals Oy (LSE:FARN) Debt-to-Equity : -0.87 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Debt-to-Equity?

Faron Pharmaceuticals Oy's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £3.13 Mil. Faron Pharmaceuticals Oy's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £8.16 Mil. Faron Pharmaceuticals Oy's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £-13.06 Mil. Faron Pharmaceuticals Oy's debt to equity for the quarter that ended in Dec. 2023 was -0.86.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Faron Pharmaceuticals Oy's Debt-to-Equity or its related term are showing as below:

LSE:FARN' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.74 Med: 0.21 Max: 5.77
Current: -0.87

During the past 12 years, the highest Debt-to-Equity Ratio of Faron Pharmaceuticals Oy was 5.77. The lowest was -1.74. And the median was 0.21.

LSE:FARN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs LSE:FARN: -0.87

Faron Pharmaceuticals Oy Debt-to-Equity Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Debt-to-Equity Chart

Faron Pharmaceuticals Oy Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.75

-1.74

1.22

-1.16

-0.87

Faron Pharmaceuticals Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.22	-2.38	-1.16	-1.42	-0.87

Competitive Comparison of Faron Pharmaceuticals Oy's Debt-to-Equity

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faron Pharmaceuticals Oy's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Debt-to-Equity falls into.

Faron Pharmaceuticals Oy Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Faron Pharmaceuticals Oy's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.134	+	8.161)	/	-13.061
	=	-0.86

Faron Pharmaceuticals Oy's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.134	+	8.161)	/	-13.061
	=	-0.86

Faron Pharmaceuticals Oy (LSE:FARN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Faron Pharmaceuticals Oy Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

FARON:Finland 4FR:Germany

Address

Joukahaisenkatu 6 B, Turku, FIN, 20520

Website

https://www.faron.com

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines